Senior Associate
Mark Loughridge

Mark is a Senior Associate in the health and life sciences team. Prior to joining Global Counsel, Mark worked in public affairs and policy at the Royal College of Surgeons of England, covering issues including the UK’s future relationship with the EU, patient safety and addressing the COVID-related backlog in elective care. Prior to this, he worked in healthcare consulting, with a particular focus on specialised commissioning and rare disease policy.  

At GC, he works with corporates and investors from the health and life sciences sector to deliver strategic solutions to policy challenges.

Recent examples of his work include:

  • Advising clients in the logistics sector on the rapidly evolving NHS procurement landscape
  • Providing analysis to clients on the ramifications of new healthcare legislation, along with government strategy related to life sciences, health data and tech innovation
  • Supporting life sciences and health IT companies in their work to navigate the political environment and develop government advocacy strategies.

Latest Insights by Mark Loughridge

Health and Life Sciences icon

How exposed is the global health system to geopolitical tensions?

Health and Life Sciences

The COVID-19 pandemic has shone a light on the fragility of the public health systems that we take for granted. As the virulence of the pandemic begins to abate across much of the world, how exposed – or prepared – are counties for the impact of war, economic sanctions, political isolation and new migratory patterns on existing health structures and systems? 

Read more
Health and Life Sciences icon

Will capacity constraints scupper the UK Government’s vision for post Brexit medical devices regulation?

Health and Life Sciences

In September, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued its long-anticipated consultation on the UK’s post Brexit medical devices regime. For all the early talk of substantial divergence from existing EU rules, the UK Government is in fact proposing greater regulatory alignment and a focus on pathways so far not offered by other major…

Read more

View all Insights by Mark Loughridge